161121-03-5

Basic information

• Product Name: (R)-1-(3, 4-DIMETHOXYPHENYL)-2-PROPANOL
• Synonyms: (R)-1-(3, 4-DIMETHOXYPHENYL)-2-PROPANOL;(R)-1-(3,4-DiMethoxy-phenyl)-propan-2-ol
• CAS NO: 161121-03-5
• Molecular Formula: C11H16O3
• Molecular Weight: 196.24
• Mol File: 161121-03-5.mol

Chemical Properties

• Boiling Point: 296.556 °C at 760 mmHg
• Flash Point: 133.153 °C
• Appearance: /
• Density: 1.063g/cm³
• Storage Temp.: 2-8°C
• PKA: 14.86±0.20(Predicted)
• CAS DataBase Reference: (R)-1-(3, 4-DIMETHOXYPHENYL)-2-PROPANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(3, 4-DIMETHOXYPHENYL)-2-PROPANOL(161121-03-5)
• EPA Substance Registry System: (R)-1-(3, 4-DIMETHOXYPHENYL)-2-PROPANOL(161121-03-5)

Safety Data

• Hazardous Substances Data: 161121-03-5(Hazardous Substances Data)

Usage

Uses

Used in Health and Wellness Applications:
Pinoresinol is used as a natural remedy for various health conditions due to its antioxidant and anti-inflammatory properties. It is particularly being investigated for its potential benefits in cardiovascular diseases and cancer prevention and treatment.
Used in Food Industry:
Pinoresinol is used as a natural additive in the food industry, where it contributes to the health-promoting properties of food products. Its antioxidant and anti-inflammatory properties make it a valuable ingredient for enhancing the nutritional value of food items.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, pinoresinol is utilized for its potential health benefits and is being studied for its use in the development of natural remedies and supplements. Its antioxidant and anti-inflammatory properties, along with its potential in cardiovascular and cancer treatment, make it a promising candidate for pharmaceutical applications.

Upstream product

• 776-99-8 3,4-dimethoxyphenylacetone 
• 6379-72-2 1,2-dimethoxy-4-(E)-propenylbenzene 
• 165821-73-8 Toluene-4-sulfonic acid (R)-3-(3,4-dimethoxy-phenyl)-2-hydroxy-propyl ester 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 37629-53-1 (E)-1,2-dimethoxy-4-(2-nitroprop-1-enyl)benzene 
• 91-16-7 1,2-dimethoxybenzene 
• 187737-37-7 propene 
• 93-15-2 1,2-dimethoxy-4-(2-propenyl)benzene 

Downstream Products

• 115247-49-9 (4,5-dimethoxy-2-nitro-phenyl)-acetone 
• 57230-44-1 Naphthalen-1-yl-carbamic acid 3,4-dimethoxy-benzyl ester 
• 1450816-79-1 (E)-ethyl 3-(4,5-dimethoxy-2-(2-methoxypropyl)phenyl)acrylate 
• 1604039-79-3 4-(4-(3,4-dimethoxyphenyl)-3-methylbut-1-yn-1-yl)-N,N-dimethylaniline 
• 1604040-03-0 2-((9-(3,4-dimethoxyphenyl)-8-methylnon-6-yn-1-yl)oxy)tetrahydro-2H-pyran 
• 1604039-14-6 4-(2-iodopropyl)-1,2-dimethoxybenzene 
• 6379-72-2 1,2-dimethoxy-4-(E)-propenylbenzene 

Relevant articles and documents

Free Radical Scavenging Activity of Essential Oil of Eugenia caryophylata from Amboina Island and Derivatives of Eugenol

Essential oil from Eugenia caryophylata was normally used to heal many different deseaces. Various chemical compositions of essential oil distilled and steamed of Moluccas Eugenia caryophylata has been investigated by many different researchers. Even though an intensive research has been carried out of the local chemotypes, a very detail study has not been fully investigated to find out the complete chemical compounds from the plant essential oil and its content associated with their biological activities. In present paper, we assess the free radical scavenging of E. caryophylata collected from Moluccas islands, Indonesia. Essential oil was extracted from leaves, buds, and stems of plant by steam distillation and analyzed using GC-FID and GC-MS. The result showed that free radical activity of essential oil, main constituent and its derivatives were analized using in vitro method. Essential oil activity from stem obtained as (0.82±0.15 μg/mL) was higher than that from bud and leaf possessing both 1,1-diphenyl-2-picrylhydrazyl (DPPH) and (2,2'-azino-bis-3-ethylbenzthizoline-6-sulphonic acid (ABTS) radical scavenging assays by sinergism of eugenol, eugenyl acetate, β-caryophylene and humulene. The activity of isoeugenol (2) (3.59±0.54 μM) and (5.0±0.53 μM) scavenging DPPH and ABTS, respectively, as derivatives eugenol was higher than (3), (4) and (5). Although (6) was active originally, it was inactive after conversion of the ester. While the change of the double bond of location to conjungation structure caused more activity scavenging radicals than the starting molecule.

BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES

BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therap

Substituted phenyl-2,3-benzodiazepines

The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting, substituted phenyl-2,3-benzodiazepines of general formula (I), in which X, R1a, R1b, R1c, R2, R3, R4, and R5 have the meanings specified in the description, to pharmaceutical

Wickerhamomyces subpelliculosus as whole-cell biocatalyst for stereoselective bioreduction of ketones

Newly isolated strains of Wickerhamomyces subpelliculosus were recognized as excellent whole-cell biocatalyst for bioreduction of various ketones. The biocatalytic properties of the new strains were demonstrated in this study by stereoselective bioreduction of acetophenone 1a, 2-heptanone 1b, phenylacetone 1c, 3,4-dimethoxyphenylacetone 1d and 1-cyclopropyl-2-(2-methoxy-4-nitrophenoxy)ethanone 1e. Our study is the first report on application of W. subpelliculosus as whole-cell biocatalyst for stereoselective bioreduction of prochiral ketones. In these processes, both the freshly harvested cell paste and the lyophilized cell powder were tested as biocatalyst using glucose or 2-propanol at various concentrations as cosubstrates for cofactor regeneration. The newly isolated strains of W. subpelliculosus showed diverse characteristics, including optimal pH, temperature and organic solvent tolerance. Bioreductions of phenylacetone 1c applying glucose as cosubstrate under various mild conditions resulted (S)-1-phenylpropanol [(S)-2c] in good to excellent conversion (c = 63.4%–99.9%) with excellent enantiomeric excess [ee(S)-2c = 98.7%–99.8%].

2,3-BENZODIAZEPINES

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES

BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders, are described. Furthermore, the use of BET protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control is described.

2, 3-benzodiazepins

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

Chemoenzymatic synthesis of enantiomerically pure syn-configured 1-aryl-3-methylisochroman derivatives

A two-step synthesis of various enantiomerically pure 1-aryl-3- methylisochroman derivatives was accomplished through asymmetric biocatalytic ketone reduction followed by an oxa-Pictet-Spengler reaction. The compounds were obtained in good to excellent yield (47-92 %) in favor of the syn diastereomers [dr (syn/anti) up to 99:1]. Enantiopure arylpropanols serving as pronucleophiles for the C-C bond-formation step were obtained by biocatalytic reduction by employing enantiocomplementary alcohol dehydrogenases, which gave access to the (S) and (R) enantiomer with up to >99 % conversion and up to >99 % ee. A two-step sequence involving a biocatalytic hydrogen-transfer reduction and a syn-diastereoselective oxa-Pictet-Spengler reaction was established to provide a series of 1-aryl-3-methylchroman derivatives with perfect enantioselectivity; PTSA = para-toluenesulfonic acid. Copyright

Mild and phosphine-free iron-catalyzed cross-coupling of nonactivated secondary alkyl halides with alkynyl grignard reagents

A simple protocol for iron-catalyzed cross-coupling of nonactivated secondary alkyl bromides and iodides with alkynyl Grignard reagents at room temperature has been developed. A wide range of secondary alkyl halides and terminal alkynes are tolerated to a

A mild and efficient flow procedure for the transfer hydrogenation of ketones and aldehydes using hydrous zirconia

A flow chemistry Meerwein-Ponndorf-Verley (MPV) reduction procedure using partially hydrated zirconium oxide via a machine-assisted approach is reported. The heterogeneous reductive system could be applied to a wide range of functionalized substrates, allowing clean and fast delivery of the alcohol products within a few minutes (6-75 min). In three examples the system was scaled to deliver 50 mmol of product.